Free Trial
NASDAQ:KPRX

Kiora Pharmaceuticals Q3 2024 Earnings Report

Kiora Pharmaceuticals logo
$3.01 +0.04 (+1.35%)
Closing price 04:00 PM Eastern
Extended Trading
$3.12 +0.11 (+3.49%)
As of 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kiora Pharmaceuticals EPS Results

Actual EPS
-$0.81
Consensus EPS
-$0.90
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Kiora Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kiora Pharmaceuticals Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Friday, November 8, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Kiora Pharmaceuticals' Q2 2025 earnings is scheduled for Friday, August 8, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Kiora Pharmaceuticals Earnings Headlines

Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 1.8% Higher - What's Next?
This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
See More Kiora Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kiora Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiora Pharmaceuticals and other key companies, straight to your email.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals (NASDAQ:KPRX) is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for immune‐mediated and fibrotic diseases of the eye and other organs. The company’s research leverages proprietary small‐molecule and peptide‐based platforms to address unmet medical needs in ocular surface disorders, dermatological conditions and mucosal repair. Kiora’s scientific approach emphasizes both anti‐inflammatory mechanisms and tissue‐regenerative pathways to restore normal function and improve patient quality of life.

The company’s lead development candidates include agents designed to treat severe dry eye disease, ocular graft-versus-host disease and other chronic inflammatory eye conditions. Kiora’s pipeline features TTHX1114, a first‐in‐class adenosine analog formulated as an eye drop to promote corneal healing, and synthetic peptides aimed at modulating immune responses. Preclinical and early‐stage clinical studies have demonstrated these candidates’ potential to reduce inflammation, accelerate tissue repair and decrease reliance on corticosteroids or immunosuppressants.

Founded in 2012 and headquartered in Salt Lake City, Utah, Kiora Pharmaceuticals has built strategic collaborations with academic institutions and contract research organizations. The company has leveraged these partnerships to advance its preclinical programs and initiate multiple Phase 1 and Phase 2 trials. Throughout its history, Kiora has expanded its intellectual property portfolio, securing patents for its peptide engineering techniques and formulation technologies. The company’s multidisciplinary scientific team brings expertise in ophthalmology, immunology, toxicology and pharmaceutical sciences.

Kiora is led by a management team with decades of combined experience in drug discovery, clinical development and regulatory affairs. At the helm is President and Chief Executive Officer Wendy H. Lewis, M.D., who previously held senior roles at established biopharmaceutical firms. Under Dr. Lewis’s guidance, Kiora aims to progress its lead candidates through pivotal clinical studies and pursue global regulatory approvals. While initially focused on North American clinical trials, the company is exploring opportunities in Europe and Asia through potential licensing agreements and investigator‐sponsored programs.

View Kiora Pharmaceuticals Profile

More Earnings Resources from MarketBeat